ImmuPharma (IMM) News Today → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free IMM Stock Alerts GBX 2.19 +0.03 (+1.39%) (As of 03:27 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImmupharma jumps amid new IP strategy for P140 technology platformlse.co.uk - April 2 at 10:32 AMIncanthera says first order from skincare deal doubleslse.co.uk - March 25 at 9:54 AMSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsmsn.com - March 15 at 10:52 AMImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsfinance.yahoo.com - March 8 at 12:04 PMImmuPharma PLC IMMmorningstar.com - February 24 at 2:58 PMUK government borrowing surplus rises in January from prior yearlse.co.uk - February 21 at 12:22 PMImmuPharma PLC (25I.SG)ca.finance.yahoo.com - January 17 at 5:12 PMEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowslse.co.uk - December 19 at 2:22 PMImmuPharma launches GBP2 million fund raise as interim loss narrowslse.co.uk - August 31 at 7:41 PMImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working Capitalmarketwatch.com - August 31 at 7:20 AMImmuPharma agrees 12 month extension to Incanthera warrant instrumentlse.co.uk - August 21 at 6:13 PMImmuPharma "absolutely delighted" to push on with new clinical trialproactiveinvestors.com - June 27 at 12:27 PMImmuPharma presses on with next phase of Lupuzor clinical trialsproactiveinvestors.com - June 19 at 7:00 PMImmuPharma "looking forward with quiet confidence" to FDA responseproactiveinvestors.com - May 24 at 8:37 AMFTSE 100 remains higher but off best with Wall Street indicated mixeduk.investing.com - May 18 at 10:40 AMImmuPharma Shares Rise on Positive Guidance From US FDA for P140marketwatch.com - May 18 at 10:40 AMImmuPharma shares jump 6.5% after FDA updateproactiveinvestors.com - May 18 at 10:40 AMImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorproactiveinvestors.com - May 18 at 10:40 AMSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029marketwatch.com - May 12 at 3:00 PMImmuPharama eyes clinical trial progressproactiveinvestors.com - May 11 at 10:19 AMImmuPharma eyes clinical trial progressproactiveinvestors.com - May 11 at 10:19 AMImmuPharma "looking forward" to upcoming FDA meetingsproactiveinvestors.com - April 27 at 1:33 PMImmuPharma partner gets FDA meeting dateproactiveinvestors.com - April 19 at 8:43 AMImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical Programmarketwatch.com - April 12 at 10:16 AMImmuPharma rises 4% after it reveals headway with lead assetproactiveinvestors.com - April 12 at 10:16 AMImmuPharma makes progress developing second indication for lead assetproactiveinvestors.com - April 12 at 5:16 AMSystemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031marketwatch.com - March 30 at 8:48 AMImmuPharma: US partner has submitted Lupuzor phase II/III trial protocolproactiveinvestors.com - March 27 at 10:33 AMImmuPharma Shares Rise on Lupus Candidate FDA Trial Submissionmarketwatch.com - March 27 at 10:33 AMImmuPharma: US partner submits Lupuzor phase II/III trial protocolproactiveinvestors.com - March 27 at 10:33 AMImmuPharma collaborates on potential 'radioactive bullet' to kill cancerproactiveinvestors.com - March 6 at 6:53 AMCutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutionsmarketwatch.com - February 14 at 2:20 PMImmuPharma expects new Lupozor study to begin in H2 2023proactiveinvestors.com - February 8 at 8:25 AMImmuPharma agrees study design with Avion for lupus programme Lupuzorlse.co.uk - February 6 at 10:13 AMImmuPharma Shares Rise After Lupuzor Trial Confirmedmarketwatch.com - February 6 at 10:13 AMImmuPharma partner agrees phase II/III clinical trial processproactiveinvestors.com - February 6 at 10:13 AMSystemic Lupus Erythematosus (SLE) Drugs Market Size 2023 Report Examines Latest Trends and Key Drivers Supporting Regional Outlook 2028marketwatch.com - January 10 at 11:10 PMUK data highlights oncoming recessionfxstreet.com - December 22 at 8:59 AMImmuPharma Shares Rise After Executives Waive Part of Salarymarketwatch.com - December 22 at 8:59 AMImmuPharma says it has ‘clear objective’ to advance lupus treatment to next clinical trial in 2023proactiveinvestors.com - December 22 at 8:59 AMImmupharma’s US partner confirms support for lupus treatment and wants to expand collaborationproactiveinvestors.com - November 11 at 8:09 AMImmupharma’s US partner confirms support for lupus treatment, wants to expand collaborationproactiveinvestors.com - November 11 at 8:09 AMAfter losing 57% in the past year, ImmuPharma plc (LON:IMM) institutional owners must be relieved by the recent gainfinance.yahoo.com - October 13 at 11:15 AMTRADING UPDATES: ImmuPharma loss narrows; MetalNRG... - Morningstarmorningstar.co.uk - October 6 at 7:00 PMImmuPharma plc (IMM.L)finance.yahoo.com - October 6 at 2:00 PMImmuPharma said it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USAproactiveinvestors.com - September 30 at 10:09 AMImmuPharma says it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USAproactiveinvestors.com - September 30 at 5:08 AMUS markets end a roller coaster session in positive territory - Proactive Investors USAproactiveinvestors.com - September 14 at 10:25 PMUS stocks push higher after yesterday's plunge - Proactive Investors USAproactiveinvestors.com - September 14 at 5:24 PMImmuPharma says its US partner for Lupuzor has received a written response from the US FDA to its Type C meeting - Proactive Investors USAproactiveinvestors.com - September 14 at 5:24 PM Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address How to camouflage a factory of 53,000 workers (Ad)"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio." Get the full story here. IMM Media Mentions By Week IMM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.000.44▲Average Medical News Sentiment IMM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼00▲IMM Articles Average Week Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BVX News SAR News ROQ News VAL News IXI News OCTP News SNG News FAB News OBI News OPTI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
